Comparison

Oroxylin A European Partner

Item no. TMO-T6S1315-10mM
Manufacturer TargetMol
CASRN 480-11-5
Amount 1 mL x 10 mM (in DMSO)
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 1 mL 1 mg 20 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Purity 0,98
Smiles COc1c(O)cc2oc(cc(=O)c2c1O)-c1ccccc1
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias 6-Methoxybaicalein, Baicalein 6-methyl ether
Shipping condition Cool pack
Available
Manufacturer - Targets
Virus Protease|||Autophagy|||HIF/HIF Prolyl-Hydroxylase
Shipping Temperature
cool pack
Storage Conditions
-20°
Molecular Weight
284, 26
Description
1. Oroxylin A (Baicalein 6-methyl ether) has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-κB pathway, and probably served as a most promising agent for CML treatment.
Bioactivity
1. Oroxylin A has various anti-tumor effects including apoptosis, cell cycle arrest, drug-resistant reversion. 2. Oroxylin A possesses abilities of inhibiting the ATRA-induced IL-6 production via modulation of LAP/LIP/CHOP in leukemia cell lines, which could providing a therapeutic strategy for RAS. 3. Oroxylin A inhibits UCP2s triggers the MPTP opening, and promotes the apoptosis in CaCo-2 cells; uncoupling protein 2 plays a key role in mitochondrial apoptotic pathway. 4. Oroxylin A inhibits N1ICD translocating to the nucleus and binding to epithelial-mesenchymal transition-related transcription factor Snail, thus suppressing the invasion and migration of MCF-7 cells. 5. Oroxylin A improves the sensitivity of K562/ADM cells by increasing apoptosis in leukemic cells and decreasing the expression of CXCR4 and PI3K/Akt/NF-kappaB pathway, and probably served as a most promising agent for CML treatment.
Pathways
Autophagy|||Metabolism|||Microbiology/Virology|||Chromatin/Epigenetic
Receptor
Others

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 1 mL x 10 mM (in DMSO)
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close